1. Introduction
Calendula officinalis L. (marigold) belongs to the Asteraceae/Compositae family, which is native to Central Europe and Mediterranean. Its flower oil is the main preparation used in cosmetic products, and contains several bioactive compounds, including terpenoids and terpenes (mainly bisabolol, faradiol, chamazulene, arnidiol and esters), carotenoids (mainly with rubixanthin and lycopene structures), flavonoids, (mainly quercetin, isorhamnetin and kaempferol aglycones) and polyunsaturated fatty acids, (mainly calendic acid) [1,2,3,4]. Calendula officinalis L. has been used for medical purposes since the XII century. The plant is reported to present several biological activities namely angiogenic, vascular regeneration, analgesic, antimicrobial, antioxidant and immunomodulatory [5,6,7,8]. In cosmetic products, calendula is used in formulations for sensitive skin and soothing products (e.g., after-sun products) among a variety of presentations, including skin, eye, hair and bath products, with recognized safety for use in cosmetics [9].
Several Calendula preparations are available for incorporation in topical formulations directed towards wound healing and for soothing inflamed and damaged skin, like extracts, tinctures, and oils [9]. There are 14 INCI designations for Calendula officinalis L. preparations at the European directory of cosmetic ingredients, and within the same designation, it is possible to find botanical preparations with different compositions, depending on the part of the plant and extraction method [10]. Calendula flower extract is the most frequently used in cosmetic products [9]. Although Calendula officinalis L. is often appointed for its anti-inflammatory activity, few studies have addressed this activity [6,11]. Loggia et al. used an animal model to demonstrate that several calendula flower preparations obtained by supercritical CO2 extraction attenuate the inflammation caused by the application of croton oil in mice ears, and that this inflammation reduction was as greater the higher the concentration of faradiol monoester they contained [11]. On the other hand, Preethi et al. showed that calendula flower extract is efficacious for treating both acute (carrageenan and dextran induced) and chronic (formalin induced) inflammation in mice, and they hypothesize it acts by inhibiting pro-inflammatory cytokines (IL-1β, IL-6, TNF-α and IFN-γ), COX-2, and subsequent prostaglandin synthesis [6]. Ukiya et al. evaluated the anti-inflammatory activity of isolated compounds from calendula flower extract using the 12-Otetradecanoylphorbol-13-acetate (TPA) induced inflammation ear edema assay in mice, but no assay was performed with the full extract [12]. Although these in vivo studies demonstrate the ability of calendula flower extract to attenuate signs and symptoms of the inflammatory response, mechanistic studies have not been carried out by the authors. Calendula officinalis L. flower ethanol extract exhibited an anti-inflammatory action through the inhibition of pro-inflammatory cytokines (IL-1β, IL-6, TNF-α and IFN-γ), and it was proposed to inhibit COX-2 through the inhibition of the enzymes gene and subsequent prostaglandin synthesis. Although, the later action mechanism was not confirmed in experimental studies [6,13,14]. Additionally, Braga et al., 2009 studied the effect of a propylene glycol extract of Calendula officinalis L. flowers on reactive oxygen species (ROS) and reactive nitrogen species (RNS) by electron paramagnetic resonance [15]. Noteworthy, there are no reports on the activity of Calendula extracts regarding the inhibition of the strong pro-inflammatory mediator nitric oxide (NO) produced by macrophages in inflammatory-related pathologies. Inflammation is triggered by many pathophysiological conditions in response to microorganisms and tissue injury. In the early phases of this process, the first line of defense is provided by macrophages, which in the presence of a stimulus, such as microbial lipopolysaccharide (LPS), a Toll-like receptor 4 agonist, produce several pro-inflammatory mediators, including nitric oxide, cytokines and prostaglandins. Under normal conditions, the release of these molecules is of paramount importance, manifesting severely, rapidly and only for a short period of time upon injury, until the resolution of the harmful stimuli. However, the abnormal production of these pro-inflammatory mediators over a long period of time may evolve to chronic inflammation-related illnesses. Therefore, molecules which are able to mitigate the production of these pro-inflammatory mediators, including NO, present an anti-inflammatory potential [16].
Therefore, to further investigate the anti-inflammatory effect of a commercial Calendula flower extract, a mouse macrophage cell line (RAW 264.7) stimulated with the strong pro-inflammatory stimulus LPS was used in this work. This was done in order to determine the extract’s influence on NO production by the inducible iNOS, expressed in innate immune cells including macrophages.
2. Materials and Methods
2.1. Materials
The calendula flower extract was purchased from Acofarma (Madrid, Spain). It consists of an extract from marigold flowers in refined soy oil, stabilized with tocopherol. The INCI designation of this cosmetic ingredient is “Calendula officinalis L. flower extract”. Lipopolysaccharide (LPS) from Escherichia coli (serotype 026:B6) was obtained from Sigma Chemical Co. (St. Louis, MO, USA) and trypsin and fetal calf serum were purchased from Invitrogen (Paisley, UK). All of other reagents were obtained from Sigma Chemical Co. (St. Louis, MO, USA).
2.2. Cellular Viability Test (AlamarBlue®)
In this experiment, macrophages were treated with different concentrations of calendula oil (from 16 to 147 μL/mL), for 24 h, at 37 °C and 5% CO2; 100 μL of resazurin solution (final in well concentration of 50 μM) was added and cell cultures were further incubated for 3 h at 37 °C protected from light. As only viable cells can reduce resazurin (a non-fluorescent blue dye) into resorufin (pink and fluorescent), their viability correlates with the magnitude of dye reduction. Quantification of resorufin was performed on a Biotek Synergy HT (BioTek Instruments, Winooski, VT, USA) plate reader at 570 nm, with a reference wavelength of 620 nm.
2.3. Assessment of Inducible Nitric Oxide Synthase Mediated NO Accumulation
RAW 264.7, a mouse leukemic macrophage cell line from the American Type Culture Collection (ATCC TIB-71) was cultured on endotoxin-free Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% (v/v) non-inactivated fetal bovine serum, 3.02 g/L sodium bicarbonate, 100 μg/mL streptomycin and 100U/mL penicillin at 37 °C in a humidified atmosphere of 95% air and 5% CO2 (carbon dioxide). During the experiments, cells were monitored through microscope observations to detect any morphological changes. Experiments were carried out at least three times.
Cells were incubated with several concentrations of the calendula oil (from 16 to 147 μL/mL), in the absence or presence of LPS (50 ng/mL) for 24 h at 37 °C. Thereafter, culture supernatants were removed and accumulated NO, as a measure of NOS activity, was assessed in cell-free culture supernatants by the Griess reaction, as previously reported [17].
2.4. Statistical Analysis
The statistical analysis was performed with GraphPad Prism8 for Windows (GraphPad Software, San Diego, CA, USA;
3. Results and Discussion
We assessed the anti-inflammatory potential of the Calendula oil using LPS-stimulated macrophages, an in vitro model of inflammation. The effect on NO production, a canonical marker of inflammation, was analyzed by measuring the accumulation of nitrites in the culture medium. Moreover, the effect of the Calendula oil on macrophages viability was also tested. Our results show that nitrite production was significantly reduced in the presence of the Calendula oil, in a dose dependent way, attaining a decrease of 50% with 147 µL/mL of the oil (Figure 1b). Importantly, macrophages’ viability was not affected by the tested concentrations of the Calendula oil (16 μL/mL to 147 μL) (Figure 1a), thus, proving the safety profile of the oil at concentrations exhibiting pharmacological activity.
The results on NO inhibition were statistically different for concentrations above 49 μL/mL control (p < 0.05), with a decrease of around 50% at 147 μL/mL.
Terpenoids and flavonoids have been considered the bioactive constituents of this plant [10]. Using the same model, other authors verified that bisabolol, kaempferol, quercetin and isorhamnetin 3-O-β-D-glucopyranoside inhibited nitric oxide production by iNOS [18,19,20,21]. Other botanical preparations, which are used in topical formulations for inflamed and injured skin, have been evaluated regarding their iNOS inhibiting ability. Gupta et al. showed that an aqueous Matricaria chamomila L. flower extract, caused a modest, but statistically significant decrease in the endogenous NO levels in RAW 264.7 cells exposed to LPS, which was more pronounced over 20 μg/mL [22]. Another study found that a methanolic Centella asiatica L. extract suppressed NO production by RAW 264.7 cells exposed to LPS in a dose-dependent manner with a maximum inhibitory effect up to 20%, in comparison with control [23]. Therefore, the test Calendula extract present a more potent iNOS inhibiting ability than Matricaria chamomila L. flower extract and Centella asiatica L. extract.
Several skin cells produce NO, and constitutive low levels of NO production seem to play a role in the maintenance of barrier function. Regulation of vasodilation, melanogenesis, and protective responses against invading pathogens are some examples of the biologic activity of NO in the skin. The dysregulation of the NO signaling cascade has been shown to be associated with several conditions and diseases (e.g., inflammatory, hyperproliferative, autoimmune skin diseases, and skin cancer). Therefore, compounds able to inhibit NO production may provide opportunities for the development of new mechanism-based therapies for skin inflammatory conditions [24]. In this view, topical medicines with Calendula flower extract can present novel benefits, in addition to the already established uses such as natural anti-inflammatory for the treatment of first-degree burns, scalds, bruises, wounds, and rashes, such as diaper dermatitis [25,26,27]. Moreover, its antimicrobial effect over both gram-positive and gram-negative may help prevent skin infection resulting from these conditions [28].
Cosmetic products containing this extract can also present a considerable advantage as adjunctive skin care in the treatment of diseases associated with iNOS activation, such as vitiligo, allergic and irritant contact dermatitis, rosacea, and melasma [29,30,31,32,33,34,35].
The experimental evidence, obtained in this work, provides scientific evidence for several reported uses of Calendula extract in cosmetic products, such as in after-sun products. UV-B exposure induces iNOS expression, while increasing the enzyme activity in skin endothelial cells, both directly and also through a TNF-α-dependent mechanism [31]. Considering calendula’s antioxidant, anti-inflammatory and wound healing activity, especially its ability for inhibiting NO production, the topical application of the flower extract is useful both for protecting the skin from sunburn and for ameliorating its symptoms, while preventing long-term consequences of UV-induced skin damage [28,30,31].
Noteworthy, this ingredient is likely to be proposed for the treatment and prevention of cancer therapy-induced skin-toxicity [36]. From the cutaneous toxicities experienced by patients, hand-foot syndrome (HFS) is among the most common [3]. Many chemotherapy agents can lead to HFS. The most commonly accepted theory of HFS pathogenesis involves direct toxicity of chemotherapeutic agents against acral epithelium, which leads to an inflammatory process due to overexpression of COX-2 in palms and plantar areas [37]. As described, inflammatory cells release prostaglandins with consequent increase in the expression of COX-2 which activates and induces oxidant generating enzymes, like NADPH oxidase, xanthine oxidase among others, which produce superoxide anion and other reactive nitrogen species like nitric oxide through activation of iNOS. [6] The use of Calendula could be part of a standardization process for HFS management since Calendula extract may inhibit pro-inflammatory cytokines and COX-2 and subsequent prostaglandin synthesis and, as shown in this work, it can also inhibit NO production [6,13,38]. Babaee et al. also showed that a Calendula extract gel could be effective in decreasing the intensity of radiotherapy-induced oropharyngeal mucositis [34].
4. Conclusions
Calendula extracts are used in a variety of cosmetics and preparations, especially for inflamed and injured skin, and have a long safety history. However, the anti-inflammatory mechanism of Calendula extracts is poorly understood. Therefore, this work investigated the ability of a commercial calendula flower extract to inhibit NO production on RAW 264.7 macrophages exposed to LPS. The results showed a dose-dependent NO inhibition up to 50%, presenting a safety profile, thus, reinforcing the anti-inflammatory activity of calendula flower extract. Overall, this study supports the usefulness of Calendula oil in the treatment of injured skin and for conditions or diseases for which iNOS contributes to the pathophysiology, such as irritative and allergic contact dermatitis, vitiligo, rosacea, melasma, psoriasis and cutaneous toxicities derived from cancer treatment. The experimental evidence, herein, obtained is also useful in supporting the claims of cosmetic products containing this botanical ingredient.
Author Contributions
Conceptualization, I.F.A. and D.S.; methodology, M.T.C. and D.S.; software, M.T.C. and D.S.; investigation, D.S.; writing—original draft preparation, M.S.F. and D.S.; writing—review and editing, D.S., M.S.F., M.T.C., I.F.A., J.M.S.-L.; supervision, M.T.C. and I.F.A.; funding acquisition, J.M.S.-L. All authors have read and agreed to the published version of the manuscript.
Funding
This work was supported by the Applied Molecular Biosciences Unit-UCIBIO which is financed by national funds from FCT/MCTES (UID/Multi/04378/2020) and by the European Regional Development Fund (ERDF), through the Centro 2020 Regional Operational Program under project CENTRO-01-0145-FEDER-000012 (HealthyAging2020). MS Ferreira acknowledges a doctoral grant from FCT ref. SFRH/BD/144864/2019.
Institutional Review Board Statement
Not applicable.
Informed Consent Statement
Not applicable.
Data Availability Statement
The data presented in this study are available in Figure 1.
Conflicts of Interest
The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Figure
Figure 1. (a) Effect of Calendula oil on macrophages viability. The assessment of metabolically active cells was performed using a resazurin bioassay. The results are expressed as a percentage of resazurin reduction relatively to control cells. Each value represents the mean ± SEM from three independent experiments. (b) Effect of Calendula oil on NO production. Anti-inflammatory activity was measured as inhibition of nitrite production, quantified by the Griess assay. The results are expressed as a percentage of nitrite production relatively to LPS. Each value represents the mean ± SEM from three independent experiments. * p < 0.05, ** p < 0.01.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
© 2021 by the authors.
Abstract
The use of calendula for its lenitive properties’ dates to the XII century. This plant contains several bioactive compounds, including terpenoids, terpenes, carotenoids, flavonoids and polyunsaturated fatty acids. Calendula flower extract is used in soothing cosmetics, such as after-sun, sensitive skin and eye contour products. The anti-inflammatory properties of this ingredient were demonstrated in an animal model, but the mechanism of action is poorly understood. Therefore, our work explored the effect of a calendula flower extract on NO production, a pro-inflammatory radical produced by nitric oxide synthase (iNOS) and highly released by innate immune cells in inflammatory-related pathologies. NO production was evoked by the Toll-like receptor 4 agonist lipopolysaccharide (LPS) in macrophages, using concentrations that did not compromise cells viability. This ingredient exhibited a dose-dependent NO inhibition, reaching 50% at 147 μL/mL without cytotoxicity. Together with previous literature, these results provide experimental evidence on the anti-inflammatory properties of calendula flower extract, as well as its usefulness in cosmetics with soothing properties and adjunctive skin care in the treatment of the diseases associated with dysregulation of the NO signaling cascade.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
; Sousa-Lobo, José Manuel 2 ; Cruz, Maria Teresa 3
; Almeida, Isabel Filipa 2
1 Laboratory of Pharmaceutical Technology, Department of Drug Sciences, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal;
2 Laboratory of Pharmaceutical Technology, Department of Drug Sciences, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal;
3 Faculty of Pharmacy, University of Coimbra, 3004-531 Coimbra, Portugal;




